- Home
- DVA vs PEN Comparison
DVA vs PEN Comparison
Compare DVA & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- PEN
- Stock Information
- Founded
- DVA 1994
- PEN 2004
- Country
- DVA United States
- PEN United States
- Employees
- DVA N/A
- PEN N/A
- Industry
- DVA Misc Health and Biotechnology Services
- PEN Medical/Dental Instruments
- Sector
- DVA Health Care
- PEN Health Care
- Exchange
- DVA Nasdaq
- PEN Nasdaq
- Market Cap
- DVA 9.4B
- PEN 9.7B
- IPO Year
- DVA 1995
- PEN 2015
- Fundamental
- Price
- DVA $119.80
- PEN $283.07
- Analyst Decision
- DVA Hold
- PEN Strong Buy
- Analyst Count
- DVA 4
- PEN 16
- Target Price
- DVA $145.00
- PEN $307.19
- AVG Volume (30 Days)
- DVA 957.9K
- PEN 493.8K
- Earning Date
- DVA 10-29-2025
- PEN 11-05-2025
- Dividend Yield
- DVA N/A
- PEN N/A
- EPS Growth
- DVA 5.63
- PEN 367.34
- EPS
- DVA 9.76
- PEN 4.14
- Revenue
- DVA $13,317,965,000.00
- PEN $1,333,798,000.00
- Revenue This Year
- DVA $6.24
- PEN $15.52
- Revenue Next Year
- DVA $3.32
- PEN $14.20
- P/E Ratio
- DVA $12.45
- PEN $67.68
- Revenue Growth
- DVA 5.14
- PEN 14.61
- 52 Week Low
- DVA $115.39
- PEN $221.26
- 52 Week High
- DVA $179.60
- PEN $310.00
- Technical
- Relative Strength Index (RSI)
- DVA 38.97
- PEN 68.37
- Support Level
- DVA $118.75
- PEN $274.20
- Resistance Level
- DVA $125.68
- PEN $283.84
- Average True Range (ATR)
- DVA 3.56
- PEN 8.42
- MACD
- DVA 0.10
- PEN 5.02
- Stochastic Oscillator
- DVA 27.51
- PEN 97.87
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.